TW202021577A - Anti-haze composition - Google Patents
Anti-haze composition Download PDFInfo
- Publication number
- TW202021577A TW202021577A TW107143465A TW107143465A TW202021577A TW 202021577 A TW202021577 A TW 202021577A TW 107143465 A TW107143465 A TW 107143465A TW 107143465 A TW107143465 A TW 107143465A TW 202021577 A TW202021577 A TW 202021577A
- Authority
- TW
- Taiwan
- Prior art keywords
- haze
- haze composition
- resveratrol
- composition
- group
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Abstract
Description
本發明係關於一種抗霧霾組合物，尤其是一種水溶解度良好的抗霧霾組合物。The present invention relates to an anti-haze composition, especially an anti-haze composition with good water solubility.
霧霾、PM2.5等空氣汙染越來越嚴重，且當人體吸入空氣汙染粒子時，可能會引起肺部的發炎及各種呼吸疾病，而已經罹患有呼吸道疾病的患者更可能會因為吸入空氣污染粒子而惡化。Air pollution such as haze and PM2.5 is becoming more and more serious, and when the human body inhales air pollution particles, it may cause lung inflammation and various respiratory diseases, and patients who have already suffered from respiratory diseases are more likely to inhale air pollution Particles and deteriorate.
為了減少空氣汙染粒子對人體的傷害，除了減少接觸空氣污染粒子外，另可以藉由攝取抗氧化劑以降低空氣汙染粒子造成的發炎反應，來提升人體的防護力。舉例而言，白藜蘆醇（resveratrol）為一種天然抗氧化劑，可以幫助細胞對抗自由基引起的損害，但是由於白藜蘆醇的水溶解度約為0.026±0.009 μg/mL，屬於難溶於水的化合物，在應用於生物體時生體利用度（bioavailability，簡稱BA）不佳，有鑑於此，若是能夠藉由與佐劑共同形成一種水溶解度良好的組合物，確實有助於改善上述的問題。In order to reduce the damage of air pollution particles to the human body, in addition to reducing exposure to air pollution particles, the intake of antioxidants can also reduce the inflammation caused by air pollution particles to enhance the protection of the human body. For example, resveratrol (resveratrol) is a natural antioxidant that can help cells fight the damage caused by free radicals, but because the water solubility of resveratrol is about 0.026±0.009 μg/mL, it is difficult to dissolve in water The compound has poor bioavailability (BA) when applied to organisms. In view of this, if it can be combined with an adjuvant to form a composition with good water solubility, it will indeed help improve the above problem.
為解決上述問題，本發明的目的是提供一種抗霧霾組合物，其具有良好的水溶解度者。To solve the above problems, the object of the present invention is to provide an anti-haze composition which has good water solubility.
本發明的抗霧霾組合物可以包含：以重量百分比計為2～5%的白藜蘆醇、8～45%的聚乙烯基吡咯烷酮，及50～90%的羥丙基-β-環糊精；其中，該抗霧霾組合物係經電紡織形成一奈米纖維。The anti-haze composition of the present invention may include: 2 to 5% by weight of resveratrol, 8 to 45% of polyvinylpyrrolidone, and 50 to 90% of hydroxypropyl-β-cyclopaste Fine; wherein, the anti-haze composition is formed by electro-spinning a nanofiber.
依據上述，本發明的抗霧霾組合物藉由聚乙烯基吡咯烷酮及羥丙基-β-環糊精的共同作用，能夠與白藜蘆醇共同形成奈米纖維，並提升白藜蘆醇的水溶解度及經皮吸收能力，進而能夠使白藜蘆醇更容易進入體內，而可以應用於預防霧霾汙染粒子對皮膚造成的傷害（例如，防止發炎及老化等症狀的發生），為本發明之功效。According to the above, the anti-haze composition of the present invention can form nanofibers together with resveratrol through the joint action of polyvinylpyrrolidone and hydroxypropyl-β-cyclodextrin, and enhance the performance of resveratrol Water solubility and transdermal absorption capacity, which can make resveratrol more easily enter the body, and can be used to prevent the damage caused by haze pollution particles to the skin (for example, to prevent the occurrence of symptoms such as inflammation and aging). The effect.
本發明的抗霧霾組合物較佳可以包含：以重量百分比計為4.0%的白藜蘆醇、16.0%的聚乙烯基吡咯烷酮及80%的羥丙基-β-環糊精，使該抗霧霾組合物於形成該奈米纖維時，具有較佳的產率。The anti-haze composition of the present invention may preferably include: 4.0% by weight percentage of resveratrol, 16.0% of polyvinylpyrrolidone and 80% of hydroxypropyl-β-cyclodextrin to make the anti-haze The haze composition has a better yield when forming the nanofiber.
本發明的抗霧霾組合物，其中，該抗霧霾組合物形成之奈米纖維的直徑較佳為300～1000 nm，如此可以有效增加活性成分的表面積進而提升皮膚吸收量來達到更佳的抗霧霾生物活性。In the anti-haze composition of the present invention, the diameter of the nanofibers formed by the anti-haze composition is preferably 300-1000 nm, which can effectively increase the surface area of the active ingredients and increase the skin absorption to achieve better Anti-haze biological activity.
為讓本發明之上述及其他目的、特徵及優點能更明顯易懂，下文特舉本發明之較佳實施例，並配合所附圖式，作詳細說明如下：In order to make the above and other objectives, features and advantages of the present invention more comprehensible, the preferred embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings:
本發明之抗霧霾組合物的一實施例，係包含以重量百分比計為2～5%的白藜蘆醇、8～45%的聚乙烯基吡咯烷酮（polyvinylpyrrolidone，簡稱PVP），及50～90%的羥丙基-β-環糊精（(2-hydroxypropyl)-β-cyclodextrin，簡稱HPβCD），例如可以包含以重量百分比計為4.0%的白藜蘆醇、16.0%的聚乙烯基吡咯烷酮及80%的羥丙基-β-環糊精（即，白藜蘆醇：聚乙烯基吡咯烷酮：羥丙基-β-環糊精＝1：4：20）。An embodiment of the anti-haze composition of the present invention contains 2-5% resveratrol, 8-45% polyvinylpyrrolidone (PVP), and 50-90% by weight. % Of hydroxypropyl-β-cyclodextrin ((2-hydroxypropyl)-β-cyclodextrin, HPβCD for short), for example, may contain 4.0% resveratrol, 16.0% polyvinylpyrrolidone and 80% of hydroxypropyl-β-cyclodextrin (ie, resveratrol: polyvinylpyrrolidone: hydroxypropyl-β-cyclodextrin=1:4:20).
該抗霧霾組合物可以藉由電紡織（elextrospinning）形成白色紡絲狀的奈米纖維，該奈米纖維的直徑約為300～1000 nm。The anti-haze composition can form white spun-like nanofibers by elextrospinning, and the diameter of the nanofibers is about 300-1000 nm.
本發明之抗霧霾組合物係形成具有良好的水溶解度之奈米纖維，因而可以促使細胞增生，並可以應用於製備預防霧霾汙染粒子對皮膚造成的傷害的製劑，該抗霧霾組合物可以與至少一醫藥學上可接受之載體共同組成該製劑，或是於該製劑中額外添加他種預防霧霾汙染粒子對皮膚造成的傷害之活性成分，以共同投予一所需個體（例如能夠以2～4 mg/cm2 的劑量塗抹於皮膚上），該載體係為一賦型劑或一添加劑，較佳係可以共同形成液狀或膠狀等各種型態之製劑，進而能夠便於該所需個體的使用。The anti-haze composition of the present invention forms nanofibers with good water solubility, thus can promote cell proliferation, and can be applied to the preparation of preparations for preventing skin damage caused by haze pollution particles. The anti-haze composition It can be combined with at least one pharmaceutically acceptable carrier to form the formulation, or additional active ingredients that prevent haze pollution particles from harming the skin can be added to the formulation to jointly administer to a desired individual (eg It can be applied to the skin at a dose of 2 to 4 mg/cm 2 ), the carrier system is an excipient or an additive, and preferably can form various types of preparations such as liquid or gel together to facilitate The use of the required individual.
為證實該抗霧霾組合物確實能夠形成具有良好的水溶解度之奈米纖維，且該抗霧霾組合物能夠進入體內，並應用於預防霧霾汙染粒子對皮膚造成的傷害，遂進行以下試驗：In order to verify that the anti-haze composition can indeed form nanofibers with good water solubility, and that the anti-haze composition can enter the body and be used to prevent the skin from being damaged by haze pollution particles, the following tests were carried out :
（A）抗霧霾組合物的製備(A) Preparation of anti-haze composition
本試驗係以如第1表所示的比例混合白藜蘆醇（RES）、聚乙烯基吡咯烷酮（PVP）及羥丙基-β-環糊精（HPβCD），並以電紡織形成各組奈米纖維，各組抗霧霾組合物之奈米纖維的產率、水溶解度同紀錄於第1表。In this experiment, resveratrol (RES), polyvinylpyrrolidone (PVP), and hydroxypropyl-β-cyclodextrin (HPβCD) were mixed in the ratio shown in Table 1, and each group was formed by electrospinning. For rice fiber, the yield and water solubility of the nanofibers of each group of anti-haze compositions are also recorded in Table 1.
第1表、本試驗各組奈米纖維的產率及水溶解度
另以掃描電子顯微鏡（scanning electron microscopy，簡稱SEM）觀察第A3～A8組抗霧霾組合物之奈米纖維的型態，其結果分別如第1a～1f圖所示，各組抗霧霾組合物之奈米纖維的直徑約為362.25±54.19、576.09±16.77、890.08±70.62、691.12±17.51、1206.87±41.40、2639.59±769.15 nm，本發明的抗霧霾組合物（即，第A3～A5組）之奈米纖維的直徑約為300～1000 nm。In addition, scanning electron microscopy (SEM) was used to observe the shape of nanofibers in the anti-haze compositions of groups A3 to A8. The results are shown in Figures 1a to 1f, respectively. The diameters of the nanofibers are about 362.25±54.19, 576.09±16.77, 890.08±70.62, 691.12±17.51, 1206.87±41.40, 2639.59±769.15 nm. The anti-haze composition of the present invention (ie, groups A3-A5) ) The diameter of nanofiber is about 300～1000 nm.
依據前述試驗結果，顯示本發明的抗霧霾組合物藉由聚乙烯基吡咯烷酮及羥丙基-β-環糊精的共同作用，能夠與白藜蘆醇共同形成奈米纖維，並進一步提升白藜蘆醇的水溶解度。According to the aforementioned test results, it is shown that the anti-haze composition of the present invention can form nanofibers together with resveratrol through the joint action of polyvinylpyrrolidone and hydroxypropyl-β-cyclodextrin, and further improve whiteness. Water solubility of veratrol.
由於第A3組抗霧霾組合物的產率為最佳，故後續試驗均以第A3組抗霧霾組合物進行。Since the yield of the anti-haze composition of the A3 group is the best, the subsequent tests are all carried out with the anti-haze composition of the A3 group.
（B）經皮吸收能力(B) Transdermal absorption capacity
本試驗係將白藜蘆醇（第B1組）及前述第A3組抗霧霾組合物（第B2組）分別溶於水後，再使豬皮吸收，最終分離豬皮的表皮層及真皮層，分析表皮層及真皮層中的白藜蘆醇的濃度，其結果如第2圖所示，第B2組的白藜蘆醇濃度隨時間增加有持續上升的趨勢，且各時間點的濃度均顯著高於第B1組，顯示本發明之抗霧霾組合物確實具有優於白藜蘆醇的經皮吸收能力。In this experiment, resveratrol (group B1) and the aforementioned anti-haze composition of group A3 (group B2) were dissolved in water, and then absorbed by pig skin, and finally the epidermis and dermis of pig skin were separated Analyze the concentration of resveratrol in the epidermis and dermis. The results are shown in Figure 2. The concentration of resveratrol in group B2 has a continuous upward trend with time, and the concentration at each time point is uniform Significantly higher than the B1 group, it shows that the anti-haze composition of the present invention does have better transdermal absorption ability than resveratrol.
依據前述試驗結果，顯示本發明的抗霧霾組合物藉由聚乙烯基吡咯烷酮及羥丙基-β-環糊精的共同作用，能夠提升白藜蘆醇的水溶解度，進而提升白藜蘆醇的經皮吸收能力，使白藜蘆醇更容易進入體內而發揮其生物活性。According to the foregoing test results, it is shown that the anti-haze composition of the present invention can increase the water solubility of resveratrol by the combined action of polyvinylpyrrolidone and hydroxypropyl-β-cyclodextrin, thereby enhancing resveratrol The transdermal absorption capacity makes it easier for resveratrol to enter the body and exert its biological activity.
（C）抗氧化能力(C) Antioxidant ability
本試驗係混合如第2表所示的待測樣品及DPPH，再偵測各組混合物於517 nm波長下的吸光值，以換算各組待測樣品的DPPH清除百分比（scavengering effect）。This experiment is to mix the test sample and DPPH as shown in Table 2, and then detect the absorbance of each group of mixtures at a wavelength of 517 nm to convert the DPPH removal percentage (scavengering effect) of each group of test samples.
第2表、本試驗各組的待測樣品
請參照第3a圖所示，本案抗霧霾組合物（第C3組）確實具有良好的DPPH清除能力。Please refer to Figure 3a, the anti-haze composition (Group C3) of this case does have good DPPH scavenging ability.
接著，混合第2表所示的待測樣品及ABTS+ 溶液，再偵測各組混合物於734 nm波長下的吸光值，以換算各組待測樣品的ABTS+ 清除百分比（scavengering effect），其結果如第3b圖所示，本案抗霧霾組合物（第C3組）仍具有良好的ABTS+ 清除能力。Next, mix the test sample and ABTS + solution shown in Table 2, and then detect the absorbance of each group of mixtures at a wavelength of 734 nm to convert the ABTS + scavengering effect of each group of test samples. The results are shown in Figure 3b, the anti-haze composition (Group C3) of this case still has good ABTS + scavenging ability.
又，混合第2表所示的待測樣品、水及六水氯化鐵（FeCl3 ‧6H2 O），再偵測各組混合物於700 nm波長下的吸光值，以換算各組待測樣品的還原能力（reducing activity），其結果如第3c圖所示，本案抗霧霾組合物（第C3組）依然具有良好的還原能力。Also, mix the test sample shown in Table 2 with water and ferric chloride hexahydrate (FeCl 3 ‧6H 2 O), and then detect the absorbance of each group of mixtures at 700 nm wavelength to convert each group to be tested The reducing activity of the sample is shown in Figure 3c. The anti-haze composition (Group C3) of this case still has good reducing activity.
依據前述試驗結果，顯示本發明的抗霧霾組合物藉由聚乙烯基吡咯烷酮及羥丙基-β-環糊精的共同作用，能夠提升白藜蘆醇的水溶解度，且對於白藜蘆醇的抗氧化能力不會造成影響。According to the foregoing test results, it is shown that the anti-haze composition of the present invention can increase the water solubility of resveratrol through the combined action of polyvinylpyrrolidone and hydroxypropyl-β-cyclodextrin, and is more effective for resveratrol. The antioxidant capacity will not affect.
（D）防止霧霾對皮膚的傷害之能力(D) The ability to prevent haze from harming the skin
本試驗係以人類角質細胞（HaCaT）作為模式細胞株，以如第3表所示的待測樣品進行前處理3小時，續以加入霧霾汙染粒子（PM），觀察各組細胞的COX-2蛋白質表現量、CPLA-2蛋白質表現量及MMP-9蛋白質表現量。In this test, human keratinocytes (HaCaT) were used as the model cell line. The samples to be tested as shown in Table 3 were pre-treated for 3 hours, followed by the addition of haze pollution particles (PM) to observe the COX- 2 Protein expression, CPLA-2 protein expression and MMP-9 protein expression.
第3表、本試驗各組的處理條件
請參照第4a～4c圖所示，霧霾汙染粒子會使角質細胞產生COX-2、CLPA-2等發炎蛋白質，亦會促進MMP-9老化蛋白質的蛋白質表現量，而本發明的抗霧霾組合物的前處理則可以防止前述蛋白質表現量提升之現象，顯示本發明的抗霧霾組合物可以預防霧霾汙染粒子對皮膚造成的傷害。Please refer to Figures 4a to 4c. The haze pollution particles can cause keratinocytes to produce COX-2, CLPA-2 and other inflammatory proteins, and also promote the protein expression of MMP-9 aging protein. The anti-haze of the present invention The pretreatment of the composition can prevent the aforementioned increase in protein expression, showing that the anti-haze composition of the present invention can prevent the skin from being damaged by haze pollution particles.
綜上所述，本發明的抗霧霾組合物藉由聚乙烯基吡咯烷酮及羥丙基-β-環糊精的共同作用，能夠與白藜蘆醇共同形成奈米纖維，並提升白藜蘆醇的水溶解度及經皮吸收能力，進而能夠使白藜蘆醇更容易進入體內，而可以應用於預防霧霾汙染粒子對皮膚造成的傷害（例如，防止發炎及老化等症狀的發生），為本發明之功效。In summary, the anti-haze composition of the present invention can form nanofibers together with resveratrol through the joint action of polyvinylpyrrolidone and hydroxypropyl-β-cyclodextrin, and enhance resveratrol The water solubility and transdermal absorption capacity of alcohol can make resveratrol easier to enter the body, and can be used to prevent the damage of the skin caused by haze pollution particles (for example, to prevent the occurrence of symptoms such as inflammation and aging). The effect of the present invention.
雖然本發明已利用上述較佳實施例揭示，然其並非用以限定本發明，任何熟習此技藝者在不脫離本發明之精神和範圍之內，相對上述實施例進行各種更動與修改仍屬本發明所保護之技術範疇，因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。Although the present invention has been disclosed using the above-mentioned preferred embodiments, it is not intended to limit the present invention. Any person skilled in the art without departing from the spirit and scope of the present invention, making various changes and modifications relative to the above-mentioned embodiments still belongs to this The technical scope of the invention is protected, so the scope of protection of the present invention shall be subject to the scope defined in the appended patent application.
無no
［第1a圖］ 試驗（A）中，第A3組抗霧霾組合物之奈米纖維的型態。 ［第1b圖］ 試驗（A）中，第A4組抗霧霾組合物之奈米纖維的型態。 ［第1c圖］ 試驗（A）中，第A5組抗霧霾組合物之奈米纖維的型態。 ［第1d圖］ 試驗（A）中，第A6組抗霧霾組合物之奈米纖維的型態。 ［第1e圖］ 試驗（A）中，第A7組抗霧霾組合物之奈米纖維的型態。 ［第1f圖］ 試驗（A）中，第A8組抗霧霾組合物之奈米纖維的型態。 ［第2圖］ 試驗（B）中，本發明抗霧霾組合物的經皮吸收能力。 ［第3a圖］ 試驗（C）中，本發明抗霧霾組合物的DPPH清除能力。 ［第3b圖］ 試驗（C）中，本發明抗霧霾組合物的ABTS+ 清除能力。 ［第3c圖］ 試驗（C）中，本發明抗霧霾組合物的還原能力。 ［第4a圖］ 試驗（D）中，本發明抗霧霾組合物的COX-2蛋白質相對表現量。 ［第4b圖］ 試驗（D）中，本發明抗霧霾組合物的CLPA-2蛋白質相對表現量。 ［第4c圖］ 試驗（D）中，本發明抗霧霾組合物的MMP-9蛋白質相對表現量。[Picture 1a] In the experiment (A), the shape of the nanofiber of the anti-haze composition of group A3. [Picture 1b] In the test (A), the shape of the nanofiber of the anti-haze composition of group A4. [Figure 1c] In the test (A), the shape of the nanofibers of the anti-haze composition of group A5. [Picture 1d] In the test (A), the shape of the nanofibers of the anti-haze composition of group A6. [Figure 1e] In the test (A), the shape of the nanofibers of the anti-haze composition of group A7. [Figure 1f] In the test (A), the shape of the nanofibers of the anti-haze composition of group A8. [Figure 2] In test (B), the transdermal absorbability of the anti-haze composition of the present invention. [Figure 3a] In test (C), the DPPH scavenging ability of the anti-haze composition of the present invention. [Figure 3b] In test (C), the ABTS + scavenging ability of the anti-haze composition of the present invention. [Figure 3c] In test (C), the reducing ability of the anti-haze composition of the present invention. [Figure 4a] In test (D), the relative expression level of COX-2 protein of the anti-haze composition of the present invention. [Figure 4b] In test (D), the relative expression level of CLPA-2 protein of the anti-haze composition of the present invention. [Figure 4c] In test (D), the relative expression level of MMP-9 protein of the anti-haze composition of the present invention.
Claims (3)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW107143465A TWI689304B (en) | 2018-12-04 | 2018-12-04 | Anti-haze composition |
| CN201911220335.3A CN111265496A (en) | 2018-12-04 | 2019-12-03 | Anti-haze compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW107143465A TWI689304B (en) | 2018-12-04 | 2018-12-04 | Anti-haze composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TWI689304B TWI689304B (en) | 2020-04-01 |
| TW202021577A true TW202021577A (en) | 2020-06-16 |
Family
ID=70993719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107143465A TWI689304B (en) | 2018-12-04 | 2018-12-04 | Anti-haze composition |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN111265496A (en) |
| TW (1) | TWI689304B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202202131A (en) * | 2020-07-10 | 2022-01-16 | 高雄醫學大學 | Use of 7,8,4’-tihydroxyisoflavone and anti-haze preparation including 7,8,4’-tihydroxyisoflavone |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1220486C (en) * | 2002-11-15 | 2005-09-28 | 董英杰 | resveratrol , piceid and its derivative and its preparation |
| WO2004103265A2 (en) * | 2003-05-26 | 2004-12-02 | Enprani Co., Ltd. | Whitening and antioxidative cosmetic composition containing resveratrol and method for preparing the same |
| BRPI0705319A2 (en) * | 2007-07-23 | 2009-07-21 | Uniao Brasileira De Educacao Manedora Da Pucrs | process for obtaining a soluble resveratrol complex and / or derivatives thereof; resveratrol complex and / or derivatives thereof; nutraceutical composition |
| CN103948933A (en) * | 2014-03-05 | 2014-07-30 | 吉林化工学院 | Resveratrol clathrate and preparation method of resveratrol clathrate preparations |
| CN106667973A (en) * | 2017-01-22 | 2017-05-17 | 西咸新区世云工研坊生物科技有限公司 | Composition for preventing haze damage and preparation method and spray of composition |
-
2018
- 2018-12-04 TW TW107143465A patent/TWI689304B/en active
-
2019
- 2019-12-03 CN CN201911220335.3A patent/CN111265496A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111265496A (en) | 2020-06-12 |
| TWI689304B (en) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016371598B2 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
| WO2018040989A1 (en) | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol | |
| US20210196783A1 (en) | New pharmaceutical use | |
| KR20190064745A (en) | Pharmaceutical composition for preventing or treating of pulmonary disease comprising mesenchymal stem cell-derived artificial nanosomes | |
| US20230255911A1 (en) | Compositions of bioactive fulvate fractions and uses thereof | |
| JPS6348849B2 (en) | ||
| WO2021213484A1 (en) | Application of radix gentianae macrophyllae and monomer compound thereof in killing mites | |
| TWI689304B (en) | Anti-haze composition | |
| JP2016196419A (en) | External preparation for skin | |
| CN108366991B (en) | Synergistic compound of pyrrolidone carboxylic acid and/or salts thereof and hyaluronic acid and/or salts thereof for the treatment and/or prevention of dryness and irritation of mucous membranes, and related pharmaceutical formulations | |
| JP5255451B2 (en) | Preparation for tissue repair or regeneration | |
| US20190321325A1 (en) | Method for treating multiple sclerosis | |
| CN114805481B (en) | Short peptide and slow release preparation with long-acting analgesic or/and long-acting local anesthetic effect by taking short peptide as carrier material | |
| CN103070834B (en) | Lyophilized powder containing esomeprazole | |
| JP4759912B2 (en) | Skin preparation | |
| TW202202131A (en) | Use of 7,8,4’-tihydroxyisoflavone and anti-haze preparation including 7,8,4’-tihydroxyisoflavone | |
| CN111346063A (en) | Chewable tablet containing ambroxol hydrochloride and clenbuterol hydrochloride and preparation method thereof | |
| JP4018358B2 (en) | Oral administration wound healing promoter | |
| US9526714B2 (en) | Method for treating skin lesions with ingenol mebutate | |
| US20230331792A1 (en) | New multi-functional oligopeptides | |
| JP2017088559A (en) | Filaggrin production enhancer | |
| TW202211914A (en) | Pharmaceutical compositions for treating arthritis and preparation methods thereof | |
| CN103284954A (en) | Inert-cellulose nasal spray | |
| Rakhimjonovich | MORPHOLOGICAL CHANGES IN HYPERTROPHIC AND POLYPOUS RHINITIS | |
| CN117529329A (en) | Compositions and methods for treating respiratory distress |